Dose-Ranging Trial with a Recombinant Urokinase (Urokinase Alfa) for Occluded Central Venous Catheters in Oncology Patients
- 1 June 2004
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Vascular and Interventional Radiology
- Vol. 15 (6), 575-579
- https://doi.org/10.1097/01.rvi.0000124950.24134.19
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Safety and Efficacy of Alteplase for Restoring Function in Occluded Central Venous Catheters: Results of the Cardiovascular Thrombolytic to Open Occluded Lines TrialJournal of Clinical Oncology, 2002
- Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy TrialJournal of Vascular and Interventional Radiology, 2001
- Therapy for thrombotic occlusion of long-term intravenous alimentation cathetersJournal of Parenteral and Enteral Nutrition, 1980
- Restoring Patency of Occluded Central Venous CathetersArchives of Surgery, 1980